Broadcast Date: October 12, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Biopharmaceutical companies are transitioning from the development of standard monoclonal antibody therapies to more intricate antibody structures and new genetic medicines. Not only are these molecules more complex, but scientists are also under tremendous pressure to understand molecular liabilities sooner and close the developability gap in a much shorter time frame. As such, analytical evaluation of these sophisticated samples is getting more complex, more numerous, and results are required in less time. As a result, investigators are in dire need of technologies that are fast and robust enough to keep up with the development pace of next-generation biotherapeutics.
In this GEN webinar, we will take a closer look at the latest technologies purpose-built to meet the challenges of the biopharmaceutical industry. For instance, we will hear details about a multi-capillary electrophoresis system that enables researchers to run multiple samples significantly faster than traditional methods, allowing for high-throughput analysis of protein purity and stability, as well as genome integrity and AAV purity. For complex protein therapeutic analysis, we will learn more about a novel LC-MS/MS QTOF instrument, as well as the software applications and advanced data processing capabilities employed to provide complete sample characterization, including impurities identification.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Produced with support from: